Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nanomaterials (Basel) ; 10(8)2020 Aug 12.
Artigo em Inglês | MEDLINE | ID: mdl-32806684

RESUMO

α-CsPbI3 quantum dots (QDs) show outstanding photoelectrical properties that had been harnessed in the fabrication of perovskite QDs solar cells. Nevertheless, the stabilization of the CsPbI3 perovskite cubic phase remains a challenge due to its own thermodynamic and the presence of surface defects. Herein, we report the optimization of the CsPbI3 QDs solar cells, by monitoring the structure, the morphology and the optoelectronic properties after a precise treatment, consisting of the conventional solvent washing with a time limited ultraviolet (UV) exposure combination, during the layer-by-layer deposition. The UV treatment compensates the defects coming from the essential but deleterious washing treatment. The material is stable for 200 h and the PCE improved by the 25% compared with that of the device without UV treatment. The photo-enhanced ion mobility mechanism is discussed as the main process for the CsPbI3 QDs and solar cell stability.

2.
Eur J Gynaecol Oncol ; 33(5): 477-9, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23185791

RESUMO

OBJECTIVE: The objective of this study was to compare the efficacy of two multi-agent chemotherapeutic regiments that were previously used at the Institution for treatment of advanced and recurrent endometrial cancer. METHODS: A retrospective review of patients with Stage III, IV, and recurrent endometrial cancer who received adjuvant chemotherapy at Roswell Park Cancer Institute over a period of 21 years. Two patient groups were defined based on treatment received: cisplatin, adriamycin, and VP-16 with or without megace (PAV-M), or carboplatin and paclitaxel (CT). RESULTS: Forty-two patients with advanced or recurrent endometrial cancer were included in this review based on regimen received. Median duration of follow up was 55 months. Treatment with PAV-M resulted in more dose modifications compared to CT group (42% vs 11%, respectively). There were no significant differences in disease-free survival or overall survival. CONCLUSIONS: PAV/PAV-M is active in patients with advanced or recurrent endometrial cancer. However, toxicity associated with this triplet regimen may limit clinical use.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Endométrio/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Idoso , Carboplatina/administração & dosagem , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Neoplasias do Endométrio/mortalidade , Etoposídeo/administração & dosagem , Feminino , Humanos , Pessoa de Meia-Idade , Paclitaxel/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...